Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares fell 5.7% during mid-day trading on Tuesday . The stock traded as low as $2.45 and last traded at $2.47. 1,091,435 shares changed hands during mid-day trading, an increase of 52% from the average session volume of 720,064 shares. The stock had previously closed at $2.62.
Separately, ValuEngine lowered Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st.
The company has a market cap of $125.26, a PE ratio of -2.17 and a beta of 2.74.
Large investors have recently made changes to their positions in the company. Alambic Investment Management L.P. bought a new position in shares of Infinity Pharmaceuticals in the 4th quarter worth approximately $158,000. Ameriprise Financial Inc. bought a new position in shares of Infinity Pharmaceuticals in the 2nd quarter worth approximately $130,000. Wells Fargo & Company MN raised its position in shares of Infinity Pharmaceuticals by 654.7% in the 4th quarter. Wells Fargo & Company MN now owns 105,136 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 91,206 shares in the last quarter. JPMorgan Chase & Co. bought a new position in shares of Infinity Pharmaceuticals in the 3rd quarter worth approximately $135,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Infinity Pharmaceuticals by 102.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 150,375 shares of the biotechnology company’s stock worth $305,000 after acquiring an additional 75,980 shares in the last quarter. 50.69% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Infinity Pharmaceuticals (INFI) Stock Price Down 5.7%” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.themarketsdaily.com/2018/03/13/infinity-pharmaceuticals-infi-stock-price-down-5-7.html.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.